Nu Skin Q3 2026 Earnings: Core Business Weakness Compresses Margins

Nu Skin Enterprises (NYSE: NUS) reported Q3 2026 revenue of $311.0 million, down 14.6% from $364.2 million a year earlier, while diluted EPS fell to a loss of $0.02 from earnings of $0.34. The core Nu Skin business contracted 19.2%, more than offsetting 13.2% growth at Rhyz, while consolidated gross margin narrowed to 65.0% and operating margin fell to 1.6%.

Core Earnings Data

Foreign exchange reduced quarterly revenue by $3.9 million, or 1.1 percentage points, leaving the constant-currency decline at 13.5%. Profit fell faster than revenue as gross profit decreased by about 21.2% and operating income dropped by approximately 76.5%.

Results included $6.3 million of charges, consisting primarily of $5.1 million in employee severance costs and $1.2 million in professional fees. Excluding specified charges, operating margin was 3.7% and diluted EPS was $0.10, both below the prior-year quarter.

Business and Segment Performance

Weakness was broad across Nu Skin’s geographic markets. Total Nu Skin revenue declined 19.2%, or 18.0% in constant currency, while Rhyz grew 13.2% as manufacturing revenue increased 19.3%.

South Korea recorded the largest regional decline, followed by Europe & Africa and Southeast Asia/Pacific. Currency had differing effects by market: it helped reported results in Mainland China but made Japan’s reported decline considerably worse than its constant-currency result.

The operating indicators for the core Nu Skin business also weakened. Customers declined 18% to 609,469, paid affiliates fell 10% to 116,449, and sales leaders decreased 13% to 26,995. The reductions across all three measures indicate that the revenue decline was accompanied by lower customer and sales-force participation.

Expense Cuts Could Not Keep Pace With Gross Profit Compression

Cost of sales was nearly unchanged at $108.8 million, compared with $107.5 million a year earlier, even though revenue fell by more than $53 million. As a result, gross profit decreased by $54.6 million and consolidated gross margin contracted by 550 basis points. The Nu Skin business itself reported a smaller margin decline, to 76.6% from 77.7%, while Rhyz manufacturing represented a larger share of consolidated revenue.

Selling expenses declined by $27.1 million, lowering the selling expense ratio to 33.2% from 35.8%. G&A expenses also fell in dollar terms, by $10.9 million, but revenue declined more quickly, causing the G&A ratio to rise to 30.2% from 28.8%. These expense reductions were insufficient to offset the loss of gross profit.

The company still produced $5.1 million of operating income, but $3.5 million of interest expense left pretax income at only $1.9 million. A $2.6 million tax provision, equivalent to a 139.3% effective tax rate, then pushed the quarter to a $0.7 million net loss. Excluding specified charges, the effective tax rate was 42.7%.

Cash and Balance Sheet

Cash decreased and inventories rose between year-end 2025 and September 30, 2026, while the company reduced total debt. The inventory increase occurred alongside falling revenue, making inventory conversion an important balance-sheet measure to monitor.

Nu Skin paid $2.9 million in dividends during the quarter and did not repurchase shares. It had $137.3 million remaining under its repurchase authorization.

Earnings Guidance

Management expects sequential revenue growth in Q4 despite another year-over-year decline. The $325 million midpoint of its Q4 revenue range would represent an increase of approximately 4.5% from Q3 revenue of $311.0 million.

The company expects approximately $5.0 million of cash-based transition costs in Q4. The substantial difference between full-year GAAP and adjusted EPS also reflects impairment-related items, a valuation allowance on deferred tax assets, inventory write-offs and other charges.

Management Commentary

CEO Ryan Napierski described the operating environment as challenging but said Nu Skin continued to see adoption of its Prysm iO platform and year-to-date revenue growth from LifePak nutritional supplements. The company also previewed anti-aging products focused on women’s health at its global convention in Japan.

Management’s near-term focus is increasing affiliate and customer engagement during the holiday season. Its expectation for sequential Q4 growth suggests that product activity and holiday execution will be central to meeting the latest revenue range.

Recent Insider Transactions

Yahoo Finance’s six-month summary classified 186,542 shares across nine transactions as purchases and 17,082 shares across three transactions as sales, resulting in net additions of 169,460 shares. However, the purchase-classified transactions were primarily stock awards rather than open-market purchases, so the positive net figure should not be interpreted as broad discretionary insider buying.

Among the latest ten reported transactions, the two disclosed sales were as follows:

The remaining eight transactions in that latest-ten list were director stock awards. These transactions alone do not establish insiders’ views on the company’s outlook.

Risks Investors Need to Watch

• Continued erosion in the core sales network: Declines in customers, paid affiliates and sales leaders could make it difficult to stabilize Nu Skin revenue, particularly because every major geographic market contracted during the quarter.
• Further margin pressure: Consolidated gross margin fell 550 basis points, and lower absolute G&A spending did not prevent the G&A ratio from increasing. Additional revenue declines could create more operating deleverage.
• Inventory and cash management: Inventory increased 7.3% from year-end while cash fell by approximately $73.7 million. If demand remains weak, slower inventory conversion could place additional pressure on liquidity or lead to write-offs.
• Tax and adjustment volatility: The Q3 tax provision turned a small pretax profit into a net loss, while the full-year GAAP outlook differs substantially from adjusted EPS because of impairment, valuation allowance and other items.
• Q4 execution: Management is relying on holiday engagement and product initiatives to produce sequential growth, even as its Q4 guidance still implies an 8% to 16% year-over-year revenue decline.

Summary

Nu Skin’s Q3 2026 results reflected broad contraction in its core business, declining customer and affiliate activity, and materially lower margins. Rhyz manufacturing provided growth but was not large enough to offset the Nu Skin decline, while expense reductions could not fully absorb the loss of gross profit. The main issues to monitor are whether holiday and product initiatives deliver the expected sequential Q4 improvement, whether core participation metrics stabilize, and how effectively the company manages margins, inventory and cash.